

23<sup>rd</sup> July, 2019

The Dy. General Manager (Listing Dept.)  
BSE Limited.,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,


**Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2019**

The presentation on unaudited Consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2019 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

**Encl.:** As above



## Q1 FY 2019-20

Revenues: Summary



## Revenues Summary | Q1 FY 2019-20

Revenues (Rs. crores)	Q1 FY20	Q1 FY19	Growth
India	907	830	9%
United States	376	334	13%
Germany	262	251	4%
Brazil	174	169	3%
Other countries	179	168	7%
Others (Incl. CRAMS)	124	120	3%
<b>Total</b>	<b>2,022</b>	<b>1,872</b>	<b>8%</b>

